Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Astria Therapeutics Inc | ATXS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.54 | 06:00:08 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.54 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.26 - 16.90 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 10.54 | USD |
Astria Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 468.87M | 54.90M | - | 0 | -72.89M | -1.33 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Astria Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATXS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.12 | 11.33 | 10.425 | 10.79 | 478,233 | -0.58 | -5.22% |
| 1 Month | 16.24 | 16.90 | 10.425 | 12.88 | 1,075,076 | -5.70 | -35.10% |
| 3 Months | 9.90 | 16.90 | 9.5488 | 13.89 | 1,057,901 | 0.64 | 6.46% |
| 6 Months | 5.64 | 16.90 | 4.26 | 11.23 | 765,876 | 4.90 | 86.88% |
| 1 Year | 10.24 | 16.90 | 4.26 | 10.89 | 482,602 | 0.30 | 2.93% |
| 3 Years | 8.53 | 16.90 | 2.36 | 10.50 | 258,984 | 2.01 | 23.56% |
| 5 Years | 8.53 | 16.90 | 2.36 | 10.50 | 258,984 | 2.01 | 23.56% |
Astria Therapeutics Description
| Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. |
